Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 11NIH 7NETWORK 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 369Ovarian Neoplasms 99Lung Neoplasms 99Neoplasms 85Small Cell Lung Carcinoma 71Breast Neoplasms 59Neoplasm Metastasis 50Triple Negative Breast Neoplasms 46Parkinson Disease 4, Autosomal Dominant Lewy Body 41Fallopian Tube Neoplasms 38Squamous Cell Carcinoma of Head and Neck 33Carcinoma 31Endometrial Neoplasms 30Uterine Cervical Neoplasms 28Colorectal Neoplasms 25Carcinoma, Ovarian Epithelial 23Head and Neck Neoplasms 19Carcinoma, Transitional Cell 18Urinary Bladder Neoplasms 17Advanced Solid Tumors 17Recurrence 15Melanoma 14Stomach Neoplasms 13Peritoneal Neoplasms 13Pancreatic Neoplasms 13Adenocarcinoma 11Lung Diseases 9Glioblastoma 9Carcinoma, Squamous Cell 9Thoracic Neoplasms 8

Interventions

Temozolomide 4Flucytosine 4vocimagene amiretrorepvec 3vorasidenib 2trametinib 2paclitaxel-Angiopep-2 conjugate 2dabrafenib 2Surgical Procedures, Operative 2OKN 007 2Chlorotoxin 2Carmustine 2talampanel 1selinexor 1pemigatinib 1pembrolizumab 1olutasidenib 1motexafin gadolinium 1exatecan 1Vincristine 1Radiation 1PF-06840003 1ONC206 1O(6)-benzylguanine 1Metabolism 1IL13-PE38 1Genetic Therapy 1Genetic Engineering 1Filgrastim 1Fentanyl 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Oligodendroglioma × Carboplatin × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡